First Nebraska Trust’s TG Therapeutics TGTX Stock Holding History

First Nebraska Trust’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$390K	Hold	7,000	–	–	0.03%	174
2026 Q2	$385K	Hold	7,000	–	–	0.03%	176
2026 Q1	$233K	Hold	7,000	–	–	0.02%	204
2025 Q4	$209K	Hold	7,000	–	–	0.02%	214
2025 Q3	$253K	Sell	7,000 -3,000	-30%	-$98.8K	0.02%	183
2025 Q2	$360K	Hold	10,000	–	–	0.03%	145
2025 Q1	$394K	Hold	10,000	–	–	0.04%	139
2024 Q4	$301K	Hold	10,000	–	–	0.03%	160
2024 Q3	$234K	Hold	10,000	–	–	0.02%	186
2024 Q2	$178K	Hold	10,000	–	–	0.02%	192
2024 Q1	$152K	Buy	+10,000	New	+$159K	0.02%	190

Other funds holding TGTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

First Nebraska Trust's TGTX Position: Q3 2026 in Review

First Nebraska Trust held its TG Therapeutics (TGTX) position steady in Q3 2026 at 7,000 shares worth $390K. The position accounts for 0.03% of the portfolio, ranked #174.

First Nebraska Trust first reported a position in TGTX in Q1 2024 and has held it in 11 quarters since. The position peaked at $394K in Q1 2025. 247 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

First Nebraska Trust held 7,000 shares of TG Therapeutics worth $390K as of Q3 2026.
First Nebraska Trust left its TG Therapeutics share count unchanged in Q3 2026.
TG Therapeutics made up 0.03% of First Nebraska Trust's portfolio in Q3 2026, its #174 holding.
First Nebraska Trust first reported a position in TG Therapeutics in Q1 2024 and has held it in 11 quarters since.
First Nebraska Trust's TG Therapeutics position peaked at $394K in Q1 2025.
247 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on First Nebraska Trust's 13F filing for Q3 2026, filed 30 Oct 2026.